JAZZ

$JAZZ chatter on StockTwits

• 
  Thomas@scor03282d

  @CAPRuccino $JAZZ supposedly bought out a San Diego based biotech, so maybe price action off of that

  View on StockTwits ↗
• 
  Jeff Siegel@LibertarianTreehugger3d

  Jazz Pharmaceuticals Targets Rare Epilepsy With New Acquisition: https://jlsfund.substack.com/p/jazz-pharmaceuticals-targets-rare $JAZZ

  View on StockTwits ↗
• 
  NOTRELOAD AI@notreload_ai4d

  $JAZZ acquires Actio Biosciences for up to $1.32 billion, adding experimental drug ABS-1230 for rare KCNT1 epilepsy with no approved treatments. https://notreload.xyz/xy/jazz-buys-actio-for-1-32b-rare-epilepsy-drug-deal/

  View on StockTwits ↗
• 
  Company@LandonCapital4d

  $JAZZ https://landoncapital.net/theres-more-to-this-buyout-jazz-pharmaceuticals-to-acquire-actio-biosciences-for-820m-upfront/

  View on StockTwits ↗
• 
  PLTRLONGDONG@PLTRLONGDONGBullish4d

  $ABCL proves the technology works. Brining to market is the last unknown. I’d expect 5B+ from partnerships with $JAZZ and $VERTEX.X ABCL575 will be bought out for royalties. ABCL386 will change cancer treatments forever ABCL688 undisclosed This is the millionaire maker even 5 years from now

  View on StockTwits ↗
• 
  Jonathan Faison@JFais4d

  $JAZZ paying up for very rare epilepsy asset 🧐

  View on StockTwits ↗
• 
  Open Outcrier@OpenOutcrier4d

  $JAZZ (+0.2% pre) Jazz Pharmaceuticals to acquire Actio Biosciences for $820M https://ooc.bz/l/110568

  View on StockTwits ↗
• 
  DonCorleone77@DonCorleone774d

  $JAZZ Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront Jazz Pharmaceuticals and Actio Biosciences announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820M upfront and up to $500M in contingent consideration. Under the terms of the merger agreement, Actio Biosciences shareholders will receive an $820M upfront payment and up to $500M in potential approval and sales milestones. As part of the transaction, and concurrently with closing, Actio Biosciences will spin out a new privately-held entity with certain management, employees and assets (not including ABS-1230 which remains with Actio Biosciences and is being acquired by Jazz). The new, independent private company will be funded by existing investors, with Jazz receiving a minority stake and certain related rights. The focus of the new company will be on genetic rare neurological diseases, which will include a clinical-stage small molecule TRPV4 inhibitor, ABS-0871, for Charcot-Marie-Tooth type 2C and other early-stage programs. With the focus on rare disease, this investment in the new entity represents a strong strategic fit for Jazz's long-term strategy. The transaction has been unanimously approved by the boards of both companies and is expected to close by the fourth quarter of 2026, subject to customary closing conditions. Jazz will fund the transaction through a combination of cash on hand and drawing on existing financing facilities.

  View on StockTwits ↗
• 
  Fangster1@Fangster15d

  $BIIB $GANX $JAZZ Very good give and take to this thread. I’ll never pretend to fully understand the science but I do understand statements made by the company. IMO they have a good idea where the 270 stands. If the 270 is a known negative, I would think some level of disclosure would be necessary after the company speak. As an investor, no issue waiting for the 360. If the 360 plays out, we’re solid gold with diamond hands. We’ll see!

  View on StockTwits ↗
• 
  Jwa68@Jwa68Bullish5d

  $GANX Khalid and Gene are very wisely beginning to position Gain as a platform company, versus a single drug company, with a vast multi target franchise opportunity in neurodegeneration. With Magellan capable of generating an endless organic pipeline of additional molecules which may be advanced to the clinic, all building upon what they have learned from GT-00287. While we will never get there unfortunately, this is similar to how $BIIB (Biogen) was started way back when and trading at just a couple dollars a share, along with $JAZZ. Ironically, Gene was one of the first analysts to initiate and recommend both names in their infancy, early on on his career as an analyst.

  View on StockTwits ↗
• 
  The Legendary Mayor@BioRichAug 5

  $REPL For those looking for useful links, hopefully this helps: NASDAQ Halts: https://www.nasdaqtrader.com/trader.aspx?id=tradehalts FDA Approvals: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process FDA CRLs: https://open.fda.gov/crltable/ Not bad to have these available for the upcoming FDA decisions for $CAPR, $NRXP, $MRNA and $JAZZ. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

  View on StockTwits ↗
• 
  Marlon John@MarlonJohnAug 4

  $JAZZ Hit With Massive Wave of Wall Street Price Target Upgrades! How High Can It Go? $JAZZ (Jazz Pharmaceuticals): Trading strongly around the $261 zone with firm upward momentum backing the tape. Major Wall Street institutions including UBS, Piper Sandler, Cowen, and Wells Fargo have heavily raised their price targets, with the street high reaching $315. A cascade of consecutive analyst upgrades signals robust institutional conviction in the company’s pipeline and long-term valuation runway. Are you riding this wave of analyst upgrades on $JAZZ?

  View on StockTwits ↗
• 
  Copy the Insider@copytheinsiderAug 4

  $JAZZ has an FDA decision coming up on August 25 for Ziihera in first-line HER2-positive gastroesophageal cancer. If approved, it would expand the drug into a much larger indication and could become an important growth driver for Jazz. Do you think the FDA approves?

  View on StockTwits ↗
• 
  Bill Turenne@WTurenneAug 4

  $JAZZ

  View on StockTwits ↗
• 
  MarketBeat Earnings@EarningsInsiderAug 4

  https://www.marketbeat.com/earnings/reports/2026-8-3-jazz-pharmaceuticals-plc-stock/ $JAZZ Jazz Pharmaceuticals Earnings Transcript

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.